Theravance Biopharma, Inc.

NasdaqGM:TBPH Rapporto sulle azioni

Cap. di mercato: US$405.1m

Theravance Biopharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

Theravance Biopharma has been growing earnings at an average annual rate of 27.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 6.7% per year.

Informazioni chiave

27.7%

Tasso di crescita degli utili

30.8%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore6.0%
Tasso di crescita dei ricavi-6.7%
Rendimento del capitale proprio-23.6%
Margine netto-73.6%
Prossimo aggiornamento sui guadagni12 Nov 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Ripartizione dei ricavi e delle spese

Come Theravance Biopharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGM:TBPH Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2462-46650
31 Mar 2462-45680
31 Dec 2357-55700
30 Sep 2355-61710
30 Jun 2351-68710
31 Mar 2349-75680
31 Dec 2251-93670
30 Sep 2252-136720
30 Jun 2252-196770
31 Mar 2254-226870
31 Dec 2155-265990
30 Sep 2159-2661080
30 Jun 2164-2641140
31 Mar 2166-2751130
31 Dec 2072-2951090
30 Sep 2083-2851120
30 Jun 2077-2701100
31 Mar 2088-2471070
31 Dec 1973-2361060
30 Sep 1960-221980
30 Jun 1960-222950
31 Mar 1957-223980
31 Dec 1860-216970
30 Sep 1849-2521010
30 Jun 1841-2601000
31 Mar 1821-2851000
31 Dec 1715-285960
30 Sep 1717-266860
30 Jun 1731-233860
31 Mar 1733-214820
31 Dec 1649-191850
30 Sep 1647-168880
30 Jun 1638-182910
31 Mar 1640-182920
31 Dec 1542-182900
30 Sep 1540-202880
30 Jun 1535-209830
31 Mar 1531-219740
31 Dec 1412-237720
30 Sep 1410-217620
30 Jun 144-203530
31 Mar 141-184480
31 Dec 130-156360

Guadagni di qualità: TBPH is currently unprofitable.

Margine di profitto in crescita: TBPH is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: TBPH is unprofitable, but has reduced losses over the past 5 years at a rate of 27.7% per year.

Accelerare la crescita: Unable to compare TBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: TBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendimento del capitale proprio

ROE elevato: TBPH has a negative Return on Equity (-23.57%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate